Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates

分组1 - Neurocrine Biosciences reported quarterly earnings of $1.88 per share, missing the Zacks Consensus Estimate of $2.25 per share, representing an earnings surprise of -16.55% [1] - The company posted revenues of $805.5 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.89%, compared to year-ago revenues of $627.7 million [2] - Neurocrine has surpassed consensus revenue estimates four times over the last four quarters [2] 分组2 - The stock has underperformed the market, losing about 3% since the beginning of the year, while the S&P 500 gained 1.4% [3] - The current consensus EPS estimate for the coming quarter is $1.75 on revenues of $736.77 million, and for the current fiscal year, it is $8.70 on revenues of $3.35 billion [7] - The Zacks Industry Rank for Medical - Drugs is currently in the bottom 42% of over 250 Zacks industries, indicating potential underperformance compared to the top 50% of ranked industries [8]